Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Total Current Liabilities (2016 - 2026)

Champions Oncology has reported Total Current Liabilities over the past 16 years, most recently at $20.7 million for Q1 2026.

  • For Q1 2026, Total Current Liabilities rose 4.06% year-over-year to $20.7 million; the TTM value through Jan 2026 reached $20.7 million, up 4.06%, while the annual FY2025 figure was $23.9 million, 10.73% up from the prior year.
  • Total Current Liabilities for Q1 2026 was $20.7 million at Champions Oncology, down from $22.1 million in the prior quarter.
  • Over five years, Total Current Liabilities peaked at $23.9 million in Q2 2025 and troughed at $15.5 million in Q1 2022.
  • A 5-year average of $20.2 million and a median of $20.7 million in 2026 define the central range for Total Current Liabilities.
  • Biggest five-year swings in Total Current Liabilities: skyrocketed 56.08% in 2022 and later decreased 9.97% in 2024.
  • Year by year, Total Current Liabilities stood at $18.7 million in 2022, then grew by 11.82% to $21.0 million in 2023, then decreased by 9.97% to $18.9 million in 2024, then grew by 17.39% to $22.1 million in 2025, then dropped by 6.61% to $20.7 million in 2026.
  • Business Quant data shows Total Current Liabilities for CSBR at $20.7 million in Q1 2026, $22.1 million in Q4 2025, and $22.7 million in Q3 2025.